About this trial
The study aims to utilize medical devices, such as the Xtreme CT and XCT 3000, to assess bone and muscle microarchitecture for various pathologies. The devices provide crucial data on bone and muscle density, aiding in understanding fracture risks associated with conditions like rheumatoid arthritis and neurological disorders. Current methods like DXA scanning have limitations in predicting fracture risks accurately due to their inability to assess cortical and trabecular microstructure. The study emphasizes the importance of evaluating cortical porosity and trabecular volume loss, especially in conditions like post-menopausal osteoporosis and sarcopenia. Additionally, it explores the impact of neurological disorders, renal insufficiency, and endocrinopathies on bone health. Furthermore, the study aims to establish a control group to differentiate pathological changes from age-related variations. Expected outcomes include a comprehensive understanding of bone microarchitecture alterations across various pathologies and the potential to improve fracture risk estimation beyond conventional methods like DEXA scanning. Ultimately, the study anticipates facilitating better management strategies to reduce fracture risks associated with these conditions.
Eligibility criteria
Qualifiers
Osteoporosis defined by: History of a documented brittle bone fracture
Bone fragility: Patient with indication for bone densitometry but no history of fracture
Rheumatoid arthritis
Spondyloarthritis
Disqualifiers
No sign written consent
anti-aromasin or GnRH agonist for at least 6 months,
corticosteroids (dose ≥ 5 mg/d for 6 months)
anti-epileptic drugs: carbamazepine, phenobarbital, phenytoin, primidone, valproic acid for at least 6 months)
Trial design
Treatments tested in this trial
- HR-pQCT
- pQCT
- DEXA